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A B S T R A C T
Although PTHrP is implicated in several cancers, its role in chemoresistance is not fully elucidated. We found
that in CRC cells, PTHrP exerts proliferative and protective effects and induces cell migration. The aim of this
work was to further study the effects of PTHrP in CRC cells. Herein we evidenced, for the first time, that PTHrP
induces resistance to CPT-11 in Caco-2 and HCT116 cells; although both cell lines responded to the drug through
different molecular mechanisms, the chemoresistance by PTHrP in these models is mediated through ERK, which
in turn is activated by PCK, Src and Akt. Moreover, continue administration of PTHrP in nude mice xenografts
increased the protein levels of this MAPK and of other markers related to tumorigenic events. The understanding
of the molecular mechanisms leading to ERK 1/2 activation and the study of ERK targets may facilitate the
development of new therapeutic strategies for CRC treatment.
1. Introduction
The parathyroid hormone-related protein (PTHrP) was found to be
secreted from various tumors and responsible for the hypercalcemia of
malignancy, being this a bad prognostic sign in malignancies (Kir et al.,
2014). However, it has been widely studied that this hormone is dis-
tributed in most fetal and adult tissues and has an important role in
fetus development and adult tissues homeostasis (Wysolmerski and
Stewart, 1998; Malakouti et al., 1996; Sidler et al., 1996; Kovacs,
2015). Today, it is recognized for its endocrine, paracrine and autocrine
modes of action (Maioli and Fortino, 2004; McCauley and Martin,
2012). In gut mucosal epithelium, it has been reported that PTHrP and
PTHrP receptor genes are widespread expressed suggesting that the
peptide exerts a local regulatory role via an autocrine/paracrine
pathway (Li et al., 1995; Watson et al., 2000). Full-length PTHrP un-
dergoes posttranslational processing, which gives rise to a family of
mature secretory peptides. PTHrP (1–34) with the N-terminal region is
capable of binding to the PTH/PTHrP receptor (PTH1R, which is a G
protein-coupled receptor), because this peptide is highly homologous
with PTH (1–34), whereas midregion and C-terminal peptides exert
their effects through uncharacterized receptors (Wysolmerski, 2012).
Cytosolic PTHrP can also use a bipartite multibasic nuclear localization
signal to translocate to the nucleus and act through an intracrine
pathway (McCauley and Martin, 2012). PTHrP was found to be ex-
pressed in numerous types of cancer (McCauley and Martin, 2012) and
in more than 90% of colorectal cancer (CRC) patients (Soki et al.,
2012). Several studies have shown that PTHrP levels are higher in less
differentiated colorectal adenocarcinomas than in those with greater
degree of differentiation and that its expression correlates with the
severity of colon carcinoma, specifically, with the differentiation, depth
of invasion, lymphatic invasion, lymph node metastasis, and hepatic
metastases (Malakouti et al., 1996; Nishihara et al., 1999, 2007).
CRC is one of the major causes of cancer death worldwide (Siegel
et al., 2015); although this disease can be cured at early stages, patients
frequently present metastases at the time-point of the occurrence of
symptoms and diagnosis, leading to a high mortality rate (Arnold et al.,
2017). Moreover, most people with metastatic CRC will eventually
present clinical failure (i.e. disease recurrence or progression) or lack of
response to first-line treatment, thus becoming potential candidates for
second-line systemic therapy. The availability of Irinotecan (CPT-11, a
topoisomerase I inhibitor, targets the topoisomerase of tumor cells in S-
phase of cell cycle) has radically altered both first- and second-line
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treatment of advanced CRC compared with the era in which the sole
treatment option in advanced disease was 5-fluorouracil (5-FU)
(Guglielmi and Sobrero, 2007). Moreover, the therapy with CPT-11-
based combinations showed better overall survival, increased the
overall tumor response rate and improved life quality in patients re-
spect to the therapy with the drug alone (Mocellin et al., 2017). Despite
these available drugs, chemoresistance is a frequent cause of treatment
failure in patients with CRC. It is known that PTHrP can mediate che-
moresistance in tumor cell lines derived from prostate and osteo-
sarcoma (Cui et al., 2016; Gagiannis et al., 2009); however, to the
present it is unknown whether PTHrP confers chemoresistance to CRC
cells.
Significant advances have been made in understanding the biology
of CRC and the underlying mechanisms related to the tumorigenesis of
this disease to facilitate new approaches for its diagnosis and therapy. It
is known that several mitogenic signaling pathways play key roles in
maintaining the growth and proliferation of CRC. Activation of ERK1/2
MAPK signaling is very common in CRC (Cheruku et al., 2015); it has
been reported that MEK/ERK signaling contributes to 5-FU resistance
and supports CRC cell growth (Yang et al., 2016a) whereas small mo-
lecular inhibitors targeting ERK signaling have shown anti-tumor ef-
fects on the colon cancer (Peng et al., 2013). Like MAPKs, there is in-
creasing evidence that the activation of PI3K/Akt pathway is associated
with CRC, and can convert differentiated human gastric or colonic
mucosa to a less differentiated and more malignant phenotype. Akt is
probably the main kinase that mediate the effects of PI3K on tumor
growth and progression (Pandurangan, 2013). Akt is overexpressed in
colon cancer, and its phosphorylation in this disease correlates with cell
proliferation and inhibition of apoptosis, as well as different clinic-pa-
thological parameters such as invasive grade, vessel infiltration, lymph
node metastasis, tumor stage and chemoresistance (Khaleghpour, 2004;
Tan et al., 2017).
A regulator of both, PI3K/Akt and MAPKs signaling pathways is Src,
which is a non-receptor protein tyrosine kinase. Since 80% of patients
with CRC shows a deregulation of Src expression and this fact is related
with metastasis and drug resistance, therefore, the inhibition of Src may
be useful for the treatment of CRC (Chen et al., 2014). The members of
PKC family are also modulators of PI3K and MAPKs pathways. These
serine/threonine kinases are classified into three subfamilies and they
are involved in multiple cell responses; for this reason, PKC isozymes
can act as therapeutic targets for several diseases. Further, significant
work has also explored the activation, mechanism, and function of PKC
isozymes in the development and progression of multiple types of
cancer (Kang, 2014).
Different cell models play an important role in understanding cel-
lular events related to pathophysiological conditions in human CRC
because it is a heterogeneous disease with three different, but partly
overlapping, molecular phenotypes reflecting different forms of DNA
instability (Ahmed et al., 2013). Caco-2 cells are derived from a human
colon adenocarcinoma, and they differentiate spontaneously in vitro
under standard culture conditions thereby exhibiting enterocyte-like
structural and functional characteristics. The human colon carcinoma
cell line HCT116, another CRC derived cell line, shows a more ag-
gressive phenotype due to hyperactivating mutations in KRAS and
PIK3CA genes (Ahmed et al., 2013; Botchkina et al., 2009). We pre-
viously showed that in both, Caco-2 cells and HCT116 cells, PTH1R is
expressed and that exogenous PTHrP modulates cell cycle progression
and exerts proliferative and protective effects via MAPKs and PI3-ki-
nase/Akt signaling pathways (Calvo et al., 2014; Lezcano et al., 2013;
Martín et al., 2014). More recently, we obtained evidence that in both
cell lines PTHrP induces cell migration via RSK/ERK1/2 signaling
pathway but not through p38 MAPK; also the peptide increases the
expression of the active form of RSK in HCT116 tumor xenografts
(Calvo et al., 2017). In view of the effects of PTHrP in vivo, the first
objective of this work was to evaluate whether the hormone modulates
the expression of other molecular markers related to tumorigenic events
in CRC tumor xenografts. The next objective of this work was to in-
vestigate the upstream pathways that modulate the mitogenic cascades
activated in response to PTHrP treatment in two CRC cell lines with
phenotypic differences (Caco-2 cells and HCT116 cells) with the aim to
also evaluate whether these molecular mechanisms are similar or dif-
ferent in these two types of tumor intestinal cells. Finally, the third
objective was to study if cell exposure to PTHrP modify the cytotoxicity
induced by CPT-11 and if so, to assess if the combination of CPT-11
with specific inhibitors of the signaling pathways that mediate the re-
sponse of tumor intestinal cells to PTHrP reestablishes the effects of the
chemotherapeutic agent in both cell lines.
2. Materials and methods
2.1. Reagents and antibodies
Human PTHrP (1–34) and Trypan Blue dye were obtained from
Sigma-Aldrich Chemical Co (St. Louis, Missouri, USA). Antibodies were
purchased from the following sources: anti-ERK 1/2 MAPK was from
abcam (Cambridge, MA, USA); anti-phospho CREB/ATF-1, anti-Cyclin
D1, anti-phospho p44/42 (phospho ERK 1/2), anti-phosphoAkt, anti-
phosphoSrc (Tyr416), anti-p27 and anti-c-Myc were provided by Cell
Signaling Technology (Beverly, Massachusetts, USA); anti-Ki67 anti-
body was from bioSB (Santa Barbara, CA, USA); anti-PTH1R receptor
antibody was from BABCO (Richmond, CA); Anti-PCKα, anti-Src, anti-
PARP, anti-Bcl-2, anti-Akt, anti-GAPDH, goat anti-rabbit peroxidase
conjugated secondary antibody and goat anti-mouse peroxidase con-
jugated secondary antibody were from Santa Cruz Biotechnology (Santa
Cruz, California, USA). PD 98059, Ro-318220 and PP1 were obtained
from Calbiochem (San Diego, California, USA). GSK690693 was from
Santa Cruz Biotechnology (Santa Cruz, California, USA). Protein size
markers were from Amersham Biosciences (Piscataway, New Jersey,
USA), PVDF (Immobilonpolyvinylidene difluoride) membranes and ECL
chemiluminescence detection kit were from Amersham (Little Chalfont,
Buckinghamshire, England). CPT-11 was gently provided by Dr. Ariel
Zwenger. All other used reagents were of analytical grade.
2.2. Xenografts in nude mice
Nude mice xenografts of HCT116 cells were established to in-
vestigate PTHrP effects in vivo since it has been shown that these cells
are tumorigenic in nude mice being its tumorigenic capacity much
greater than that of Caco-2 cells (McIntyre et al., 2015; Tong et al.,
2011). 1× 106 HCT116 cells were subcutaneously injected into the left
dorsal flanks of 6-week-old male LAE:NIH (S)-Fox 1numice. We refer
this mice strain as “nude”. Four days after inoculation, animals were
randomized (blindly) into control and treatment groups (n=6/group).
Mice were administered daily with PTHrP (40 μg/kg in 100ul PBS), or
an equal volume of vehicle solution, as control, by intratumoral injec-
tion (2 groups in total; each group represents an experimental unit). We
selected this dose of the peptide based in previous studies performed by
us and by other investigators with PTH and/or PTHrP in rodents (Frolik
et al., 1999; Stewart et al., 2000; Zhou et al., 2003; Calvo et al., 2017).
The mice were sacrificed and tumors were removed and weighted after
20 days of PTHrP treatment. Tumor size was calculated according to the
following formula: tumor volume (mm3)= tumor width (mm2) x tumor
length (mm)/2 (Wang et al., 2002). At the end of the trial the average
weights were 0.30 g ± 0.11 (standard deviation) and 0.4 g ± 0.10
(standard deviation) for control tumors and treated tumors, respec-
tively whereas the average volumes were 0.21mm3 ± 0.08 (standard
deviation) and 0.26mm3 ± 0.08 (standard deviation) for control tu-
mors and treated tumors. Tumor tissue was fixed with 4% neutral
buffered formaldehyde solution for immunohistochemistry assay. All
experiments with animals were approved by a local animal committee
for ethics (CICUAE-UNS) and were carried out in accordance with the
National Institutes of Health guide for the care and use of Laboratory




Paraffin embedded sections were deparaffinised, re-hydrated and
pre-treated using heat mediated antigen retrieval (using a pressure
cooker) with sodium citrate buffer (10mM, pH 6) for 15min. After the
antigen retrieval step, tissue sections were washed and blocked in 30%
H2O2, and the primary antibodies (anti-phospho CREB/ATF-1, anti-
phospho ERK, anti-ERK 1/2, anti-Cyclin D1 and anti-phospho Akt) were
added for overnight incubations at 4 °C. Immunohistochemical staining
was carried out manually using ABCAM Detection IHC Kit (abcam,
Cambridge, MA, USA) according to the manufacturer's instructions.
Finally, the slides were monitored under microscope and the reaction
was stopped with distilled water, counterstained with hematoxylin,
dehydrated, and coverslipped. Staining was visualized using a light
microscope.
2.4. Staining assessment and scoring
Phospho-ERK 1/2, ERK 1/2, phospho-Akt, Cyclin D1 and phospho-
CREB/ATF-1 expression levels were classified semi-quantitatively based
on the total combined scores of the percentage of positively stained
tumor cells together with the staining intensity. A tumor was scored as
‘0’ if< 5% of tumor cells were stained positive, ‘1’ if 5–50% were
stained positive, ‘2’ if > 50–90% of the cells were stained positive and
‘3’ if the 90–100% of cells were stained positive. The staining intensity
was scored as ‘0’ if no staining of cells occurred or if there was only
weak staining, ‘1’ if there was moderate staining and ‘2’ in cases of
strong staining. The final score of all proteins expression was defined as
‘low protein expression’ if the sum of the positivity score and the
staining intensity score was 0–1, ‘middle protein expression’ if the sum
was 2–3 and ‘high protein expression’ if the sum was 4–5 (Allen, 2006;
Yang et al., 2010). In each case, at least three different tumor areas
were evaluated and the mean of the results was taken as the final ex-
pression score. The scoring procedure was carried out twice by two
independent pathologists who had no knowledge of the data and cor-
responding hematoxylin and slides. The concordance rate between the
two pathologists was> 95%.
2.5. Determination of proliferative index
The proliferative indices in untreated and treated tumors were de-
termined by staining tumor sections with an anti-Ki67 antibody, as
previously described (Terraneo et al., 2013). To determine the index in
both tumors, positive and total nuclei were quantified in five random
microscopic areas at 40×by two independent observers with 100%
agreement in their observations. Weak and strong nuclear labeling was
considered positive. Both indices were expressed as a percentage of
stained cells to total cells.
2.6. Cell culture and treatment
The human colorectal cell lines Caco-2 and HCT116 (from the
American Type Culture Collection, Manassas, Virginia) were cultured at
37 °C in DMEM (Sigma-Aldrich Chemical Co., St. Louis, Missouri, USA)
containing 10% FBS (Natocor, Córdoba, Argentina), 1% non-essential
acids, 100 UI/mL penicillin, 100mg/mL streptomycin and 50mg/mL
gentamycin in a humid atmosphere of 5% CO2 in air. Cultures were
passaged every 2 days with fresh medium. All experiments were per-
formed using passages less than 15. Experimental cultures were grown
to 80% confluence in serum-containing medium, and then cells were
serum-deprived 24 h before the addition of 10−8 M PTHrP (1–34) at
different times. This dose of exposure was selected because we pre-
viously studied the effects of PTHrP (1–34) 10−8 M in Caco-2 cells and
HCT116 cells expressing PTH/PTHrP receptor (Calvo et al., 2014;
Martín et al., 2014). In previous study we showed the relevance of
exogenous PTHrP in the tumor intestinal cellular response since we
observed that endogenous PTHrP (produced by the tumor cell) did not
influence on cellular response (Martín et al., 2014). Where indicated,
cells were pretreated for 30min with Ro-318220 (an inhibitor of PKC),
PD 98059 (an inhibitor of MEK, which is the upstream kinase of ERK1/
2), PP1 (an inhibitor of Src) or GSK690693 (an inhibitor of Akt).
Control conditions were performed by addition of an equivalent volume
of DMSO (which is the vehicle of all used inhibitors). In previous works
we confirmed the effectiveness of the kinases inhibitors PD 98059 and
Ro-318220 (Calvo et al., 2011, 2014; Martín et al., 2014), whereas PP1
and GSK690693 doses were chosen according to previous works in vitro
(Levy et al., 2009; Maat et al., 2009; Saksena et al., 2005).
2.7. Measurement of CPT-11 effects
CPT-11 cytotoxicity was assessed by Trypan blue dye exclusion test.
Caco-2 and HCT116 cells were seeded in a 24-well plate until 80%
confluence. Cells were treated with or without PTHrP 10−8 M and/or
CPT-11 (10 μM) for triplicates for 5 days or 1 day, respectively. The
dose of this drug was chosen according to previous works (Erdem et al.,
2017; Maitra et al., 2014). Where indicated, both cell lines were pre-
incubated with PD 98059, GSK690693 or the vehicle. After the treat-
ment, cells were washed with PBS buffer, released from the cultured
dish using trypsin-EDTA, incubated with 0.4% of Trypan Blue stain and
counted in a Neubauer chamber observed in a microscope. Cells were
counted per field and the number of cells that excluded the stain (viable
cells) was determined in each condition.
2.8. Western blot analysis
Cells were washed with PBS buffer plus 25 mMNaF and 1mM
Na3VO4, and lysed in buffer containing 50 mMTris–HCl (pH 7.4), 150
mMNaCl, 3 mMKCl, 1 mM EDTA,1% Tween-20, 1% Nonidet P-40,
20 μg/mL aprotinin, 20 μg/mL leupeptin, 1 mMphenylmethylsulfonyl
fluoride (PMSF), 25 mMNaF, and 1mM Na3VO4. The lysates were in-
cubated on ice for 10min, vortexed for 45 s, and maintained on ice for
another 10min. After centrifugation at 14 000g and 4 °C for 15min, the
supernatant was collected and proteins were quantified by the Bradford
method. Lysate proteins dissolved in 5× Laemmli sample buffer were
separated (30μg/lane) using SDS-polyacrylamide gels (10% acryla-
mide) and electrotransfered to PVDF membranes. After blocking with
5% nonfat milk in TBST buffer (50 mMTris pH 7.2–7.4, 200 mMNaCl,
0.1% Tween-20), the membranes were incubated overnight with the
appropriate dilution of primary antibody in TBST with 1% nonfat milk.
After washing, membranes were incubated with the appropriate dilu-
tion of horse radish peroxidase-conjugated secondary antibody in TBST
with 1% non-fatmilk. Finally, the blots were developed by ECL with the
use of Kodak BioMax Light film and digitalized with a GS-700 Imaging
Densitomer (Bio-Rad, Hercules, California,USA).
2.9. Stripping and reproving membranes
The complete removal of primary and secondary antibodies from
the membraes was achieved by incubating the membranes in stripping
buffer (62.5 mMTris–HCl pH 6.8, 2% SDS and 50mM β-mercap-
toethanol) at 55 °C for 30min with agitation. Then, membranes were
washed for 10min in TBST (1% Tween-20) and blocked, as indicated
above, for 1 h at room temperature. After that, membranes were ready
to reprove with the corresponding antibodies.
2.10. Statistical analysis
Data obtained from three in vitro independent experiments per-
formed in triplicate were presented as mean ± SD. Student's t-test
(two-tailed, equal variance) was used to determine significant
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differences between two groups of data. p values of< 0.05 and < 0.01
were considered as statistically significant, and are indicated by aster-
isks (* and **, respectively) or hash symbol (# and ##, respectively).
3. Results
3.1. PTHrP modulates molecular mechanisms related to tumorigenic events
in nude mice tumor xenografts
RSK signaling is involved in many cancers, controls oncogenic
processes through the regulation of transcription factors and/or cellular
modulators. Theses kinases also regulate protein synthesis, and there-
fore, RSK-mediated translational control may play a critical role in the
regulation of tumorigenic cellular events (Park and Cho, 2012). Re-
cently, we obtained evidence that PTHrP induces the activation of RSK
in HCT116 tumor xenografts. Since in vitro the peptide activates RSK via
ERK1/2 signaling pathway but not through p38 MAPK in HCT116 cell
line (Calvo et al., 2017), therefore our first objective was to investigate
whether the hormone also modulates the expression of other molecular
markers related to tumorigenic events (such as MAPKs) in CRC tumor
tissues. Immunohistochemistry analysis of these tumor xenografts
showed increased immunoreactivity scores of active ERK 1/2 and total
ERK 1/2 in tumors treated with PTHrP respect to the levels observed in
tumor treated with PBS, which is the vehicle of the hormone (Fig. 1a
and b left and right panels). PTHrP treatment did not change the pro-
tein levels of the active form of Akt (Fig. 1c). As in vitro we previously
obtained evidence that PTHrP increases the protein expression of Cyclin
D1, a positive cell cycle regulator, and also induces CREB and ATF
phosphorylation, two transcription factors that play important roles in
the regulation of cell proliferation through MAPK pathways (Martín
et al., 2014), then we evaluated the protein levels of Cyclin D1 and
phospho-CREB/ATF-1 in HCT116 xenografts treated or untreated with
PTHrP. Representative immunohistochemical staining shown in Fig. 1d
and e (left and right panels) revealed that the hormone increased the
immunoreactivity score of Cyclin D1 and active CREB/ATF-1 and as
expected, the localization of all transcription factors evaluated was
nuclear whereas active and total ERK 1/2 MAPKs and Akt were ob-
served in the cytoplasm and nucleus of HCT116 cells. To provide ad-
ditional evidence of the role of PTHrP as a regulator of tumor pro-
liferation markers expression in vivo, we also evaluate the level of Ki67,
which is a nuclear protein expressed in proliferating cells and is a
marker for cell proliferation of solid tumors. Based on the im-
munostained cells, we then obtained the proliferation index, expressed
in percentage, from untreated and treated tumors. As shown in Fig. 1f,
PTHrP increased the protein levels of Ki67 whereas the proliferation
index was significantly greater in treated tumors than in non-treated
tumors.
3.2. PTHrP induces the phosphorylation and activation of Src kinase in
Caco-2 cells and HCT116 cells
The activation of ERK1/2 signaling is very common in colon cancer
and is vital for the growth of CRC cells (Cheruku et al., 2015; Setia
et al., 2014), We previously observed that PTHrP stimulates cell pro-
liferation and cell cycle progression through ERK MAPK in tumor in-
testinal cells (Martín et al., 2014; Calvo et al., 2014). Moreover, our
recent studies revealed that PTHrP can promote cell migration through
RSK/ERK MAPK in Caco-2 cells and HCT116 cells (Calvo et al., 2017).
Since we also detected ERK activation in vivo, then our next goal was to
investigate signal transduction pathways through which PTHrP triggers
ERK 1/2 MAPK activation in Caco-2 cells and HCT116 cells.
It has been reported that stimulation of the Ras/Raf/MEK/ERK
cascade can occur by activation of the Src kinase (McCubrey et al.,
2007). Furthermore, increased Src activity has been found in many
cancers, including colon cancer (Steeg, 2016). To evaluate whether Src
is part of the PTHrP signaling mechanism in tumor intestinal cells, we
first monitored Tyr416 phosphorylation state of c-Src because in this
enzyme, autophosphorylation in its kinase domain at Tyr416 alters its
conformation and increases its intrinsic kinase activity (Chen et al.,
2014). Caco-2 cells and HCT116 cells were exposed to PTHrP for the
times indicated in Fig. 2a and Fig. 2b followed by Western blot analysis
of cell lysates with anti-c-Src-phospho Tyr416. As shown in Fig. 2a (left
panel) and 2b (left panel), PTHrP transiently increases the phosphor-
ylation on Tyr416 of c-Src, with maximal effects at 60–120min and at
1–3min for Caco-2 cells and HCT116 cells, respectively. Immunoblot
analysis using an anti-Src antibody revealed that the protein levels of
total Src were no different in the absence or presence of PTHrP at the
times indicated, demonstrating a true increase in the phosphorylation
status of Src (Fig. 2a and b, lefts panels). However, the treatment with
the hormone for 60 and 90min induces changes in c-Src protein ex-
pression in HCT116 cells (Fig. 2b, right panel). The fact that the dou-
bling time of HCT116 cells is shorter than that observed in Caco-2 cells
(21 h and 36 h, respectively) and that the metabolic activity in
HCT116 cells is higher than in Caco-2 cells may explain these findings
showing that, after PTHrP treatment, Src is activated faster in
HCT116 cells than in Caco-2 cells.
3.3. PKCα levels decreased and increased in Caco-2 cells and HCT116 cells,
respectively, after PTHrP treatment
The stimulation of Ras/Raf/MEK/ERK cascade can also occur by
direct activation of Raf via PKC (Plotnikov et al., 2011). Based on their
structural and activation characteristics, PKC family can be classified
into three subfamilies: conventional or classic PKC isozymes (cPKCs; α,
βI, βII, and γ), novel or non-classic PKC isozymes (nPKCs; δ , ε, η, and θ),
and atypical PKC isozymes (aPKCs; ζ , ι, and λ). In cancer, many of these
isozymes play a critical role in cell proliferation, survival, invasion,
migration, apoptosis, angiogenesis, and anticancer drug resistance
(Kang, 2014). With the aim to evaluate whether PKC family is also part
of the PTHrP signaling mechanism in tumor intestinal cells, then we
analyze the protein levels of PKCα in these cells treated with the hor-
mone because it is known that the down-regulation of its expression
increases cellular proliferation, decreases differentiation and enhances
the transformed phenotype of Caco-2 cells (Scaglione-Sewell et al.,
1998). Caco-2 cells and HCT116 cells were exposed to PTHrP for the
times indicated in Fig. 3a followed by Western blot analysis of cell ly-
sates with anti-PKCα antibody. As shown in Fig. 3a, PKCαprotein levels
decreased in Caco-2 cells exposed with PTHrP for 60min whereas the
treatment with the hormone for 30min increased protein expression of
this isozyme in HCT116 cells. These results suggest that after PTHrP
treatment, PKCα levels decreased and increased in Caco-2 cells and
HCT116 cells, respectively.
3.4. PKC, Src and Akt signaling pathways modulate the phosphorylation
and activation of ERK 1/2 induced by PTHrP in tumor intestinal cells
It has been reported that Src causes colon cancer through multiple
downstream signaling pathways, including PI3K/Akt (Chen et al.,
2014). With respect to PKC, during cancer cell proliferation and sur-
vival several of their isozymes stimulate survival or proliferation
through different signaling pathways such as PI3K/Akt (Kang, 2014).
As we previously observed that PTHrP activates PI3K/Akt in tumor
intestinal cells (Calvo et al., 2014; Martín et al., 2014), then we first
evaluated if PKC and Src signaling pathways are involved in the
phosphorylation/activation of Akt induced by PTHrP in these cells. To
that end, Caco-2 cells and HCT116 cells were pre-incubated with a
specific inhibitor of PKC, Ro-318220 (200 nM) or with a specific in-
hibitor of Src, PP1 (10 μM) and then treated for 60min or 1min with
PTHrP, respectively. These times were selected because previously we
observed that the phosphorylation/activation of Akt significantly in-
creased at 60min and at 1min after PTHrP treatment in Caco-2 cells
and HCT116 cells, respectively (Martín et al., 2014; Calvo et al., 2014).
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Western blot analysis using an anti-phospho-(Ser473) Akt antibody
(which recognizes the active form of Akt) revealed that both inhibitors
totally suppressed hormone-dependent Akt phosphorylation (Fig. 3b).
Immunoblot analysis using an anti-Akt antibody revealed that the
protein levels of total Akt were no different in the absence or presence
of PTHrP at the times indicated, demonstrating a true increase in the
phosphorylation status of Akt (Fig. 3b, left and right panels). DMSO,
which is the vehicle of both inhibitors, was used in control cells.
In view of the participation of Src and PKC in the PTHrP signaling
mechanism in tumor intestinal cells and taking into account that PI3K/
Akt pathway is necessary for the activation of ERK 1/2 in many cell
types (Ebi et al., 2013; Steelman et al., 2011) then our next objective
was to investigate whether Src, PCK and Akt kinases are involved in the
activation of ERK 1/2 MAPK triggered by PTHrP in both cell lines. To
that end, these cells were pre-incubated with a specific inhibitor of Akt,
GSK690693 (50 nM), with a specific inhibitor of PKC, Ro-318220
(200 nM), or with a specific inhibitor of Src, PP1 (10 μM), and then
treated for 60min or 1min with PTHrP, respectively. These times were
selected because previously we observed that the phosphorylation/ac-
tivation of ERK1/2 significantly increased at 60min and at 1min after
PTHrP treatment in Caco-2 cells and HCT116 cells, respectively (Calvo
et al., 2017; Martín et al., 2014). Western blot analysis using specific
anti-phospho-ERK 1/2 antibody (which recognizes the active form of
ERK 1/2 MAPK) revealed that all inhibitors employed totally sup-
pressed hormone-dependent MAPK phosphorylation in both, Caco-
2 cells and HCT116 cells (Fig. 4a). Immunoblot analysis using an anti-
ERK 1/2 antibody revealed that the protein levels of total ERK 1/2 were
no different in the absence or presence of PTHrP at the times indicated,
demonstrating a true increase in the phosphorylation status of ERK 1/2
(Fig. 4a, left and right panels). DMSO, which is the vehicle of these
Fig. 1. Effects of PTHrP administration (40μg/kg) in
tumor xenografts.
Representative staining pattern of protein expression
detected by immunohistochemistry (positivity+ in-
tensity) in HCT116 xenograft tumors. Tumor sections
were stained with (a) anti-phospho ERK 1/2, (b)
anti-ERK 1/2, (c) anti-phospho Akt (d) anti-Cyclin
D1 (e) anti-phospho CREB/ATF1 and anti-Ki67 an-
tibodies. Images are from tumor untreated (left) or
treated with PTHrP (right). (a) Score of 2 + 1 in
control tumors and 3 + 2 in treated tumors, (b)
score of 3 + 0 in control tumors and 3 + 2 in treated
tumors, (c) score of 3 + 2 in control tumors and
3 + 2 in treated tumors (d) score of 1 + 1 in control
tumors and 2 + 2 in treated tumors, (e), score of
2 + 2 in control tumors and 3 + 2 in treated tumors,
(f) The proliferation indices (based on Ki67 labelling,
expressed in percentage) from untreated and treated
tumor are shown. Magnification× 400.
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inhibitors, was used in control cells. Taken together, these results
suggest that Src and PKC play a role upstream in the signaling me-
chanism leading to Akt and ERK 1/2 activation by PTHrP in both cell
lines. Also, once activated, Akt is able to activate ERK 1/2.
Based on these results, the next approach was performed with an
antibody against to type 1 PTH receptor (PTH1R) to confirm that the
cellular response is specific to PTHrP/PTH1R interaction. To that end,
Caco-2 cells and HCT116 cells were pre-incubated with the antibody
(5 μg/mL) or with a non-specific IgG (5 μg/mL), as a control, followed
by the treatment with PTHrP (1–34) for 1 h and 1min, respectively. As
shown in Fig. 4b, Western blot analysis using specific anti-phospho-ERK
1/2 antibody revealed that the antibody against PTHrP receptor totally
suppressed hormone-dependent MAPK phosphorylation in both, Caco-
2 cells and HCT116 cells. The membranes were stripped and reblotted
with anti-GAPDH antibody to ensure the equivalence of protein
loading. These findings confirm that ERK activation in cell derived from
CRC is exclusively by PTHrP/PTH1R interaction.
3.5. The expression changes of c-Myc and Cyclin D1 induced by PTHrP are
dependent on ERK 1/2 signaling pathway in tumor intestinal cells
In CRC, it is well established the transcriptional activation of certain
genes such as c-Myc and Cyclin D, which are two positive cell cycle
regulators associated with tumor intestinal cells proliferation (El
Khoury et al., 2016). In vitro we previously demonstrated that PTHrP
increases the amount of these proteins in tumor intestinal cells (Martín
et al., 2014) and herein we showed that the hormone also up-regulates
Cyclin D protein expression in vivo; furthermore, this peptide positively
modulates cell cycle progression and changes the expression of other
proteins involved in cell cycle regulation via MAPK pathway (Calvo
et al., 2014). In order to investigate whether the effect of PTHrP on the
expression of c-Myc and Cyclin D1 is dependent upon ERK 1/2
pathway, tumor intestinal cells were pre-incubated in the presence or
absence of PD98059 (20 μM), a specific inhibitor of MEK1/2 (which are
upstream kinases of ERK1/2), and then treated with the hormone for 1
or 2 h followed by immunoblot analysis using specific antibodies. As
shown in Fig. 4c, when Caco-2 cells were incubated with the inhibitor,
the PTHrP response is reverted. Taken together, these results indicate
that the effect of PTHrP on the protein expression of c-Myc and Cyclin
D1 is dependent of ERK 1/2 MAPK pathway.
3.6. PTHrP attenuates the effect of CPT-11 in tumor intestinal cells
The results shown by us in previous studies and in the present work
demonstrated the key role of PTHrP in the modulation of molecular
mechanisms related to tumorigenic events both in vitro and in vivo.
Since PTHrP can mediate chemoresistance effects in other models (Cui
et al., 2016; Gagiannis et al., 2009), then we investigated whether the
peptide can also modify tumor intestinal cell response to the che-
motherapeutic agent CPT-11. To that end Caco-2 cells and HCT116 cells
were treated with CPT-11 (10 μM) alone or in combination with PTHrP.
As shown in Fig. 5 (left panel), counting live cells by means of Trypan
blue dye exclusion revealed that the treatment with the drug sig-
nificantly decrease the number of viable Caco-2 cells respect to the
number of viable Caco-2 cells untreated (dark purple bars). Fig. 5 (right
panel, dark purple bars) shows a significant decrease of the number of
viable HCT116 cells treated with the drug respect to the number of
viable HCT116 cells untreated. However, the treatment with PTHrP for
5 days in Caco-2 cells or 24 h in HCT116 cells attenuated the cytotoxi-
city induced by CPT-11 (light purple bars, Fig. 5 left and right panels).
We selected these times of PTHrP treatment because in previous studies
we observed that the maximum response in cell proliferation is
achieved at 5 days and 1 day of PTHrP exposure in Caco-2 cells and
HCT116 cells, respectively.
3.7. The effects of CPT-11 on the levels of pro-apoptotic and anti-
proliferative factors necessary for the cytotoxic response in intestinal tumor
cells are counteracted by PTHrP
The increase in the expression of certain negative cell cycle reg-
ulators such as p21, p27 and p53 as well as the decrease in the ex-
pression of molecules with anti-apoptotic activity such as Bcl-2 can
Fig. 2. PTHrP activates Src kinase pathway in tumor intestinal cell lines. (a) Caco-2 cells and (b) HCT116 cells were grown and incubated in the absence or
presence of PTHrP (1–34) 10−8 M for 30–120 min or 1–120 min, respectively. Western blot analysis of cell lysates was carried out using anti-phospho (Tyr416) Src
and anti-Src antibodies. The membranes were stripped and reblotted with anti-GAPDH antibody to ensure the equivalence of protein loading. Representative
immunoblots and the quantification by scanning densitometry of three independent experiments are shown; means ± S.D. are given. *P < 0.05, **P < 0.01.
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predict a favorable evolution in patients with CRC treated with CPT -11
(Charara et al., 2004). In addition, the activation of the apoptotic ef-
fector caspase-3 and consequently the cleavage of its substrate, poly-
ADP ribose polymerase (PARP), are expected events once the CRC
tumor cells respond to CPT-11 (Yang et al., 2016b). Taking into account
that PTHrP exerts a protective effect under apoptotic conditions
(Lezcano et al., 2013) and also negatively modulates several cell cycle
inhibitors (Calvo et al., 2014), we decided to evaluate the expression of
relevant molecular markers associated with these cellular responses in
both Caco-2 cells and HCT116 cells treated with CPT-11 alone or in
combination with PTHrP. For this purpose, the cells were initially ex-
posed to the drug or the drug plus the hormone for 8, 24 and 48 h; these
times were selected according to previous studies carried out in our
laboratory (Calvo et al., 2014; Lezcano et al., 2013). Western blot
analysis of the protein from lysates of HCT116 cells using anti p27, anti
Bcl-2 and anti-cleaved PARP antibodies, revealed that both, the in-
crease in protein levels of p27 inhibitor and the cleaved form of PARP,
as well as the decrease in protein levels of Bcl-2 induced by the treat-
ment with CPT-11 were reversed by exposure of the cells to PTHrP plus
CPT-11 (Fig. 6 top panel), suggesting that PTHrP decreases the sensi-
tivity to CPT-11 in HCT116 cells through the modulation of the protein
expression of at least Bcl-2 and p27 and through the modulation of the
activity of caspase-3. However, we did not observed changes in the
expression levels of these proteins in the Caco-2 cell line due to treat-
ment with CPT-11 or with PTHrP plus CPT-11 (Fig. 6 bottom panel),
suggesting that the drug affects the viability of this cell line through
other mechanisms than those observed in the tumor intestinal line
HCT116.
3.8. The ERK signaling pathway participates in the chemoresistance to CPT-
11 induced by PTHrP
Previous works revealed that p38 MAPK pathway is involved in the
sensitivity to CPT-11 and suggest that the level of phosphorylated p38
could be used as a marker of clinical resistance to CPT-11, and that the
signaling pathway of p38 MAPK could be a therapeutic target to
overcome the resistance to CPT-11-based chemotherapies in the CRC
(Paillas et al., 2011). In addition, it has been observed that the acti-
vation of ERK in the HCT116 cell line can generate resistance to other
antitumor agents such as Erlotinib, which inhibits the kinase activity of
the epidermal growth factor receptor (Chen et al., 2007). Since PTHrP
activates ERK MAPK both in vitro and in vivo and several signaling
pathways activated by the hormone converge in the activation of ERK
MAPK, then we evaluated whether the use of a specific inhibitor of this
signaling pathway (PD98059 20mM) restores the sensitivity of in-
testinal tumor cells to CPT-11, even in the presence of PTHrP. Counting
live cells by means of Trypan blue dye exclusion revealed that the
blockade of ERK restored the inhibition of cell growth due to the
treatment with the chemotherapeutic in Caco-2 cells and in
HCT116 cells (Fig. 7a light purple bars marked with the symbol ##).
Fig. 3. (a) Effects of PTHrP on PCKα expression. Caco-2 cells and HCT116 cells were treated with or without PTHrP (1–34) 10−8 M for 15–60 min and 15–120 min,
respectively. Proteins from lysates were prepared as described in Methods, separated on SDS-PAGE, and immunoblotting using anti- PCKα antibody. In order to
evaluate the equivalence of protein content among the different experimental conditions, blotted membranes were reproved with anti-GAPDH antibody.
Representative immunoblots and the quantification by scanning densitometry of three independent experiments are shown; means ± SD are given. **P < 0.01,
with respect to the corresponding control. (b) Involvement of PKC and Src signaling pathways in the phosphorylation and activation of Akt induced by
PTHrP. Caco-2 cells and HCT116 cells were pre-incubated for 30min with Ro-318220 (200 nM) or PP1 (10 μM) and then exposed to PTHrP (1–34) 10−8 M for 60 min
or 1 min, respectively, followed by Western blot analysis of proteins from cell lysates using anti-phospho (Ser473) Akt antibody. Blotted membranes were reproved
with anti-Akt and anti-GAPDH antibodies in order to demonstrate a true increase in the phosphorylation status of Akt and to ensure the equivalence of protein
loading, respectively. Representative immunoblots and the quantification by scanning densitometry of three independent experiments are shown; means ± SD are
given. **P < 0.01, with respect to the corresponding control.
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We observed that the inhibition of Akt pathway by the use of the Akt
inhibitor GSK690693 (50 nM) also restore CPT-11 action in Caco-2 cells
and in HCT116 cells (Fig. 7b, light purple bars marked with the symbol
#, left panel, and the symbol ##, right panel). Taken together, these
results suggest that PTHrP attenuates the cytotoxicity of CPT-11
through the ERK pathway and through the Akt pathway which lead to
ERK 1/2 MAPK activation in both Caco-2 cells and HCT116 cells.
4. Discussion
Herein we provide several evidences of the role of exogenous PTHrP
as a regulator of tumor proliferation markers expression in vivo. It have
been reported the effects of PTHrP overexpressed in tumor xenografts of
Lovo cells (Shen et al., 2007); however, and since that the vast majority
of PTHrP actions are paracrine in nature (Maioli and Fortino, 2004), we
decided to evaluate the action of the hormone produced from an ex-
ternal source and therefore we injected PTHrP into the tumors. We
previously reported the activation in vitro of mitogenic signaling path-
ways in Caco-2 cells and HCT116 cells after PTHrP exposure (Calvo
et al., 2014, 2017; Martín et al., 2014). In this work, we showed, for the
Fig. 4. (a). Involvement of PKC, Src and Akt signaling pathways in the phosphorylation and activation of ERK 1/2 induced by PTHrP. Caco-2 cells and
HCT116 cells were pre-incubated for 30min with Ro-318220 (200 nM), PP1 (10 μM) or GSK690693 (50 nM) and then treated with PTHrP (1–34) 10−8 M for 1 h or
1 min, respectively. Western blot analysis of cell lysates was carried out using an anti-phospho ERK 1/2 antibody. The membranes were stripped and reblotted with
anti-ERK 1/2 and anti-GAPDH antibodies in order to demonstrate a true increase in the phosphorylation status of ERK 1/2 and to ensure the equivalence of protein
loading, respectively. Representative immunoblots and the quantification by scanning densitometry of three independent experiments are shown; means ± S.D. are
given. *P < 0.05. (b). ERK 1/2 activation in cell derived from CRC is exclusively by PTHrP/PTH1R interaction. Caco-2 cells and HCT116 cells were pre-
incubated with the antibody anti-PTH1R or with a non-specific IgG followed by the treatment with PTHrP (1–34) for 1 h and 1min, respectively. Western blot
analysis of cell lysates was carried out using an anti-phospho ERK 1/2 antibody. GAPDH was measured in the same immunoblot by stripping the membrane and re-
incubating with the specific antibody in order to ensure the equivalence of protein loading. (c). The expression changes of c-Myc and cyclin D1 induced by
PTHrP are dependent on ERK 1/2 signaling pathway in intestinal tumor cells. Caco-2 cells were pre-incubated for 30min with PD98059 (20 μM) and then
treated in presence or absence of PTHrP (1–34) 10−8 M for 1 h (right panel), or 2 h (left panel). Western blot analysis of cell lysates was carried out using anti-c-Myc
(left panel) and anti-Cyclin D1 (right panel) antibodies. The membranes were stripped and reblotted with anti-GAPDH antibody to ensure the equivalence of protein
loading. Representative immunoblots and the quantification by scanning densitometry of three independent experiments are shown; means ± S.D. are given.
*P < 0.05, **P < 0.01.
Fig. 5. PTHrP decreases the response of intestinal tumor cells to CPT-11.
Caco-2 (a) and HCT116 (b) cells were treated with PTHrP and/or CPT-11
(10μM) for 5 days (a) or 1 day (b). The number of viable cells was counted by
Trypan blue staining using a Newbauer chamber. The average of the results
obtained from three independent experiments is shown. *P < 0.05,
**P < 0.01. (For interpretation of the references to color in this figure legend,
the reader is referred to the Web version of this article.)
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first time, that intratumoral PTHrP administration in nude mice xeno-
grafts increases the levels of several positive regulators of cell pro-
liferation, including ERK MAPK. The fact that we did not observe the
same effect on the activation of Akt signaling suggests that PTHrP in
vivo may exert its effects through ERK MAPK but independently of Akt.
Other investigators have observed that PTHrP administrated in animals
exerts anabolic effects in cancellous and cortical bone and/or improves
bone strength in osteopenic rodents and humans (Stewart et al., 2000),
while the present investigation provides, to our knowledge, additional
evidence demonstrating that exogenous PTHrP regulates signaling
pathways associated with proliferation in animal models. Taken
together, these findings emphasize the endocrine/paracrine action of
the hormone in in vivo models.
The results showed in this work indicate that PTHrP induces the
phosphorylation and activation of Src kinase in Caco-2 cells and
HCT116 cells. The phenotypic differences between both cell types due
to variants in genes mutations (Ahmed et al., 2013) may explain the
fact that the hormone up-regulates the protein levels of Src, at least at
the times studied, in HCT116 cells but not in Caco-2 cells. Recently, we
observed that PTHrP activates the tumorigenic β-catenin pathway in-
dependently of Wnt signaling and in both type of cells derived from
CRC studied by us, Caco-2 cells (with APC mutant) and HCT116 cells
Fig. 6. PTHrP reverses the changes in the ex-
pression levels of p27, Bcl-2 and cleaved PARP
due to treatment with CPT-11 in the HCT16 cell
line but not in the Caco-2 cells. HCT116 (a) and
Caco-2 (b) cells were cultured and incubated in the
absence or presence of PTHrP (1–34) 10−8 M for
8–48 h. Analysis by Western blot technique of cell
lysates was carried out using anti-p27, anti-Bcl-2 and
anti-PARP antibodies. The membranes were re-in-
cubated with anti-actin antibody to ensure equiva-
lence of protein loading.
Fig. 7. (a) PTHrP attenuates the cytotoxicity of CPT-11
through the ERKMAPK pathway and (b) through the Akt
pathway which lead to ERK 1/2 MAPK activation. Caco-2
(right panels) and HCT116 cells (left panels) were pre-in-
cubated with the inhibitors PD98059 (20mM) (a) or
GSK690693 (50 nM) (b) for 30 min and then treated with
PTHrP and/or CPT-11 for 5 days (right panels) or 1 day (left
panels). The number of viable cells was counted by Trypan
blue staining using a Newbauer chamber. DMSO was used as
a vehicle of both inhibitors. The average of the results ob-
tained from 2 independent experiments is shown.
**P < 0.01, #P < 0.05, ##P < 0.01. (For interpretation
of the references to color in this figure legend, the reader is
referred to the Web version of this article.)
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(with APC wild type). We also found that some mitogenic signaling
pathways mediate this activation by phosphorylation (Martin et al.,
2014; Martin M.J., personal data). Under this scenario, in HCT116 cells
perhaps the increase of the transcriptional activity mediated by β-ca-
tenin may lead to the induction of Src gene expression. In addition, the
presence of hyperactivating KRAS mutation in HCT116 cells (Ahmed
et al., 2013) may explain the increased Src protein expression because
in these cells treated with PTHrP, RAS may modulate Src expression via
RAS-ERK pathway and/or via RAS-ERK-β-catenin pathway. So, al-
though APC mutation is not present in HCT116 cell line (Ilyas et al.,
1997), it is possible that other mechanisms acting in concert to facilitate
β-catenin nuclear translocation and the subsequent increase of the
transcriptional activity mediated by β-catenin leading to the modula-
tion of Src expression. More experiments are needed to corroborate this
idea.
Src activity is increased in 80% of CRC patients, which indicates its
importance in the disease (Lieu and Kopetz, 2010). An activating mu-
tation of the Src gene is found in 12% of patients. This mutation ac-
counts for only a small proportion of Src activation in colon cancer.
Furthermore, several other studies have not detected mutations in this
kinase in colon cancer (Chen et al., 2014). These data suggest that ac-
tivated Src is more likely a mediator of cellular signals that are induced
upstream of Src. The role of Src in colon cancer progression is con-
firmed by its increased activity with the progression from benign polyps
to carcinoma to metastatic cancer. Src is higher in human early-stage
malignant polyps but not in benign polyps, which suggests that Src is
significantly related to the progression of colon cancer (Irby and
Yeatman, 2000). Other studies have also shown that Src activity is
much higher in metastatic colon cancer than in non-metastatic colon
cancer (Chen et al., 2014).
Our results suggest that after PTHrP treatment, PKCα levels de-
creased and increased in Caco-2 cells and HCT116 cells, respectively. It
is known that PKC isozymes can exhibit similar expression patterns and
roles in multiple types of cancer. However, in some cases, they can
show specific expression and function that is dependent on the type of
cancer (Kang, 2014). Several studies showed discordant results respect
to the role of PKCα in colon cancer progression: although increasing
evidence shows that PKCα does participate in growth arrest and cancer
suppression in the intestine epithelium (Garg et al., 2014), a recent
study has suggested that PKCα activation is involved in the activation of
ERK1/2/NF-κB through the tissue factor/VIIa/PAR2 pathway and this
signaling pathway leads to enhanced proliferation, migration, and
survival for the colon cancer cell line SW620 (Wu et al., 2013). Alter-
nately, PKCα can also enhance cell adhesion and anticancer resistance
through a different signal pathway than that used during anti-pro-
liferation. High migratory activity of colon cancer cells is related to
high PKCα and low E-cadherin expression (Masur et al., 2001), in this
context, the down-regulation of PKCα may increase the sensitivity to
anticancer agents (Kang, 2014).
Herein we demonstrated that Src signaling pathway modulates the
phosphorylation of Akt and ERK 1/2 induced by PTHrP in tumor in-
testinal cells. It is known that Src regulates PI3K by directly phos-
phorylating the p85 subunit of PI3K and inhibiting the PI3K negative
regulator phosphatase (PTEN). Src recruits PI3K to an activated mem-
brane compartment and phosphorylates p85 at Tyr688. The phosphor-
ylation of this p85 subunit leads to the reduced inhibition of another
PI3K subunit, the catalytic p110. These series of events lead to an in-
crease in PI3K activity. Src also reduces the action of PTEN, which in-
hibits PI3K. The activation of PI3K increases the phosphorylation of Akt
via phosphoinositide-dependent kinase (PDK). In addition, Src regulates
Ras-Raf-MEK-ERK1/2 pathway activating c-Ras, which is the main
regulator of MAPK. Ras activates Raf, which in turn activates MEK, and
MEK activates ERK 1/2 (Frame, 2004).
In this work, studies with Ro 31–820, which is a specific inhibitor of
the activity of several PKC isoforms, showed that PTHrP regulates the
activation of Akt and ERK 1/2 through of at least one isozyme of PKC.
PKCα is an isozyme that also has been broadly studied in relation to
cancer (Marengo et al., 2011). PKC α is positively modulated in its
expression and/or in its activation (by phosphorylation) to promote the
aggressive behavior of tumor intestinal cells (Kang, 2014). We suppose
that PKCα may be involved in this response to PTHrP in Caco-2 cells as
well as in HCT116 cells since in both tumor intestinal cell lines, the
treatment with the phorbol ester TPA under conditions that activate
PKC (100 nM, 15min) significantly increased the phosphorylation of
PKCα whereas this effect was reversed in TPA-treated cells and in the
presence of Ro 31–820 at a dose of 200 nM (Martín M.J., unpublished).
Other colleagues demonstrate that bradykinin acts as a proliferative
agent in breast cancer cells activating intracellular pathways such as
PKCα, Akt and ERK1/2 and that PKCα is involved in the activation of
ERK 1/2 (Greco et al., 2006).
It has been reported that PKCα is phosphorylated and activated by
Src favoring the aggressive phenotype of intestinal tumor cells and the
consequent progression of CRC (McKinley et al., 2013). Studies em-
ploying the normal cell line PC12, derived from rat pheochromocy-
toma, showed that PKC-ι and PKC-ζ, which are two atypical PKC, are
also phosphorylated and activated by Src (Wooten et al., 2001). Ad-
ditionally, PI3K has been shown to regulate the activity of PKC in
cancer, in an AKT-independent manner through poorly characterized
mechanisms that leads to survival, cytoskeletal rearrangement and
transformation (Vivanco and Sawyers, 2002). Luna-Ulloa and collea-
gues demonstrated that PKC ζ interacts with β-catenin in cells derived
from CRC. These investigators found that PKC ζ activity regulates the
nuclear localization of β-catenin in a mechanism that does not involve
β-catenin degradation (Luna-Ulloa et al., 2011). Perhaps in our ex-
perimental model at least one isozyme of PKC activated by PTHrP acts
in concert with others signaling pathway to facilitate β-catenin nuclear
translocation and the subsequent increase in the transcriptional activity
mediated by β-catenin leading to the induction of PKC α expression in
HCT116 cells. More studies are necessary to elucidate which PKC iso-
zyme/s is/are involved in the activation of ERK and Akt and which are
the mechanisms involved in the regulation of the expression and/or
activation of PKC.
We previously showed that PTHrP induced the expression of Cyclin
D1 and c-Myc in tumor intestinal cells (Martín et al., 2014) and herein
we demonstrated that the hormone upregulates the expression of both
positive regulators of cell proliferation through ERK 1/2 MAPK. The
proto-oncogene MYC is one of several well-known transcription factors
involved in the genesis and progression of many types of cancer acting
as a main regulator of the expression of genes involved in cell pro-
liferation and invasion. In CRC, c-Myc protein expression is known to be
up-regulated in up to 70% of cases (Boudjadi and Beaulieu, 2016);
moreover, it has been found that RTK/RAS/MEK/ERK pathway en-
hance c-Myc protein stabilization by phosphorylation (Boudjadi et al.,
2016) and that the phosphorylation by ERK1/2 of LRP6 (which is a key
component of the Wnt pathway) with the consequent up-regulation of
c-Myc may provide a unique point of convergence between MAPK and
Wnt/β-catenin signalings during oncogenesis (Lemieux et al., 2015).
Perhaps in both tumor intestinal cell lines studied in this work, the
increase in this onco-protein expression by PTHrP may be due to c-Myc
protein stabilization by phosphorylation together with its up-regula-
tion. More experiments are necessary to confirm this hypothesis. With
respect of Cyclin D1, this and other cell cycle-regulatory proteins are
essential for cell cycle progression from G1 to S phase; there is evidence
that its expression can be down-regulated by PKCα but markedly is up-
regulated by PKCε through ERK pathway. Again, these findings high-
light opposing actions of PKC family members and the role of ERK,
which converge in the modulation of Cyclin D1 expression, as im-
portant regulators of tissue homeostasis and tumorigenesis in the in-
testine (Pysz et al., 2014).
Herein we evidenced, for the first time, that PTHrP induces re-
sistance to CPT-11, which is a topoisomerase inhibitor, in Caco-2 and
HCT116 cells. PTHrP induces resistance to others topoisomerase
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inhibitors such us doxorubicin and mitoxantrone in tumor cell lines
derived from osteosarcoma (Gagiannis et al., 2009). However, it is
known that PTHrP can also mediate chemoresistance to docetaxel in
tumor cell lines derived from prostate (Cui et al., 2016). The antitumor
activity of this drug is based on stabilization of the microtubule dy-
namics and thereby disruption of the cell cycle (de Weger et al., 2014).
Taken together, these data indicate that PTHrP-induced resistance is
not only specific to topoisomerase inhibitors.
This work shows that ERK signaling pathway participates in the
chemoresistance to CPT-11 induced by PTHrP in cells derived from
CRC. Chemotherapeutic drug resistance is a frequent cause of treatment
failure in CRC patients. Understanding the cellular mechanisms that
lead to this resistance should allow an improvement in the treatment of
CRC. CPT-11 resistance in CRC appears to develop by a few mechanisms
including low intratumor level of the active metabolite SN-38, a de-
crease in expression of topoisomerase I, change in the activity of the SN-
38-Topo I- DNA complex, and changes in downstream events such as
suppression of apoptosis, cell cycle alterations, or enhancement of DNA
repair (Hammond et al., 2016). Recently, the use of compounds that
target components of the ERK signaling pathway, such as Raf or MEK
inhibitors, has led to a substantial improvement in the clinical outcome
in another type of cancer, metastatic melanoma, and has shown pro-
mising clinical activity in other types of tumors. However, the response
and efficacy of these drugs are highly variable and is mainly limited by
the development of resistance. Both intrinsic and acquired resistance to
Raf and MEK inhibitors are frequently associated with the persistence of
ERK signaling, which implies the need for more innovative approaches
to address the pathway (Samatar and Poulikakos, 2014).
5. Conclusion
In conclusion, this work expands our knowledge about the mole-
cular mechanisms modulated by exogenous PTHrP in vivo and in vitro.
We demonstrated that continue administration of this hormone in nude
mice xenografts activates ERK 1/2 MAPK and other components of
mitogenic signaling pathways. Also, our results indicate that Src, PKC
and Akt play a role upstream in the signaling mechanism leading to
ERK 1/2 MAPK activation by PTHrP in two CRC cell lines which are
phenotypically different. Furthermore, herein we demonstrate, for first
time, that PTHrP induces resistance to a chemotherapeutic drug in CRC
cells and that this effect is mediated through ERK signaling (Fig. 8).
The investigations of the last decade indicate that PTHrP is a
bioactive factor in the initiation, growth and invasion of several car-
cinomas. In 2007, Nishihara and colleagues revealed that 95% of pa-
tients with CRC overexpress PTHrP being the level of expression higher
in the less differentiated adenocarcinomas than those with the highest
degree of differentiation (Nishihara et al., 2007). Despite these inter-
esting data, a recent publication that carries out an exhaustive review of
articles reveals only 29 reported cases of CRC associated with PTHrP
and hypercalcemia (Galindo et al., 2016), we think that this situation
may imply a lack of knowledge of the existence of many more cases of
CRC in which PTHrP is one of the factors that contribute to the genesis
and progression and even chemoresistance responses of this disease.
The results shown in the present work emphasize the key role of
ERK as a mediator of tumorigenic events and chemoresistance induced
by PTHrP in cells derived from CRC. The understanding of the mole-
cular mechanisms involved in the activation of ERK 1/2 and the study
of ERK signaling targets may facilitate the development of new ther-
apeutic strategies for CRC treatment.
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